International Journal of Clinical Pharmacy

, Volume 38, Issue 5, pp 1080–1086 | Cite as

A web-based training program to support chronic kidney disease screening by community pharmacists

  • Pankti A. GheewalaEmail author
  • Gregory M. Peterson
  • Syed Tabish R. Zaidi
  • Luke Bereznicki
  • Matthew D. Jose
  • Ronald L. Castelino
Research Article


Background Community pharmacists’ role in screening of several chronic diseases has been widely explored. The global health burden of chronic kidney disease is high; however, the progression and adverse outcomes can be prevented or delayed by detecting and treating the disease in its initial stages 1–3. Therefore, a web-based training program was developed to enhance pharmacists’ knowledge and skills required to perform a chronic kidney disease screening service in a community setting. Objective The aim of this study was to evaluate the impact of a web-based training program on community pharmacists’ knowledge and skills associated with chronic kidney disease screening. As secondary aim, pharmacists’ satisfaction with the training program was assessed. Setting Community pharmacy practice. Method A web-based training program was developed by four pharmacists and a nephrologist. Quantitative data was collected by employing a self-administered, web-based questionnaire, which comprised a set of five multiple-choice knowledge questions and one clinical vignette to assess skills. A nine-item Likert scale was used to determine pharmacists’ satisfaction with the training program. Main outcome measure Pharmacists’ knowledge and skills scores at pre and post-training, reliability of the Likert scale, and the proportion of responses to the individual nine items of the satisfaction survey. Results Fifty pharmacists participated in the pre-questionnaire and 38 pharmacists completed the web-based training and post-questionnaire. Significant differences were observed in the knowledge scores (p < 0.001) and skills scores (p < 0.001) at pre- and post-training. Cronbach’s alpha for the nine-item satisfaction scale was 0.73 and the majority pharmacists (92.1–100 %) were satisfied with the various aspects of the training program. Conclusion The web-based training program positively enhanced pharmacists’ knowledge and skills associated with chronic kidney disease screening. These findings support further development and widespread implementation of the training program to facilitate health promotion and early identification of chronic kidney disease in a community setting.


Chronic kidney disease Screening Web-based training program Continuing professional education Pharmacist 



We would like to acknowledge all community pharmacists who participated in the study; Edmond Gardiner for providing assistance with pharmacy recruitment; and Peter Gee for the input towards web-based development of the training program.


This study was funded by the Tasmanian Community Fund and supported by the Division of Pharmacy, School of Medicine, Faculty of Health, University of Tasmania.

Conflicts of interest


Supplementary material

11096_2016_330_MOESM1_ESM.pdf (68 kb)
Supplementary material 1 (PDF 67 kb)


  1. 1.
    Ayorinde AA, Porteous T, Sharma P. Screening for major diseases in community pharmacies: a systematic review. Int J Pharm Pract. 2013;21(6):349–61.CrossRefPubMedGoogle Scholar
  2. 2.
    Bereznicki BJ, Peterson G, Jackson S, Walters EH, George J, Stewart K, et al. Uptake and effectiveness of a community pharmacy intervention programme to improve asthma management. J Clin Pharm Ther. 2013;38(3):212–8.CrossRefPubMedGoogle Scholar
  3. 3.
    Stafford L, Peterson GM, Bereznicki LR, Jackson SL, van Tienen EC, Angley MT, et al. Clinical outcomes of a collaborative, home-based postdischarge warfarin management service. Ann Pharmacother. 2011;45(3):325–34.CrossRefPubMedGoogle Scholar
  4. 4.
    Williams M, Peterson GM, Tenni PC, Bindoff IK, Curtain C, Hughes J, et al. Drug-related problems detected in Australian Community Pharmacies: The PROMISe Trial. Ann Pharmacother. 2011;45(9):1067–76.CrossRefPubMedGoogle Scholar
  5. 5.
    Peterson GM, Fitzmaurice KD, Kruup H, Jackson SL, Rasiah RL. Cardiovascular risk screening program in Australian community pharmacies. Pharm World Sci. 2010;32(3):373–80.CrossRefPubMedGoogle Scholar
  6. 6.
    Benrimoj SI, Frommer MS. Community pharmacy in Australia. Aust Health Rev. 2004;28(2):238–46.CrossRefPubMedGoogle Scholar
  7. 7.
    Weiner DE. Public health consequences of chronic kidney disease. Clin Pharmacol Ther. 2009;86(5):566–9.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Levey AS, Coresh J, Balk E, Kausz AT, Levin A, Steffes MW, et al. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med. 2003;139(2):137–47.CrossRefPubMedGoogle Scholar
  9. 9.
    Naghavi M, Wang H, Lozano R, Davis A, Liang X, Zhou M, et al. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: A systematic analysis for the Global Burden of Disease Study 2013. The Lancet. 2015;385(9963):117–71.CrossRefGoogle Scholar
  10. 10.
    Australia & New Zealand Dialysis & Transplant Registry. Incidence of End Stage Kidney Disease: 37th Annual Report. 2014. Accessed 2 Dec 2015.
  11. 11.
    Australian Institute of Health and Welfare. Dialysis and kidney transplantation in Australia: 1991–2010. Cat. no. PHE 162. Canberra: AIHW. 2012. Accessed 29 Nov 2015.
  12. 12.
    Mathew T, Corso O. Review article: Early detection of chronic kidney disease in Australia: which way to go? Nephrology (Carlton). 2009;14(4):367–73.CrossRefPubMedGoogle Scholar
  13. 13.
    Jose MD, Otahal P, Kirkland G, Blizzard L. Chronic kidney disease in Tasmania. Nephrology (Carlton). 2009;14(8):743–9.CrossRefPubMedGoogle Scholar
  14. 14.
    Cass A, Chadban S, Gallagher M. Kidney Health Australia. The economic impact of end-stage kidney disease in Australia: Projections to 2020. 2010. Accessed 8 March 2016.
  15. 15.
    Lopez-Vargas PA, Tong A, Sureshkumar P, Johnson DW, Craig JC. Prevention, detection and management of early chronic kidney disease: a systematic review of clinical practice guidelines. Nephrology (Carlton). 2013;18(9):592–604.CrossRefPubMedGoogle Scholar
  16. 16.
    Salgado TM, Moles R, Benrimoj SI, Fernandez-Llimos F. Pharmacists’ interventions in the management of patients with chronic kidney disease: a systematic review. Nephrol Dial Transplant. 2012;27(1):276–92.CrossRefPubMedGoogle Scholar
  17. 17.
    Low BY, Halai HK. Exploring the roles of pharmacists in the prevention of chronic kidney disease: a qualitative study. Int J Pharm Pract. 2013;21:25.Google Scholar
  18. 18.
    QKidney®-2014 risk calculator. 2014. Accessed 21 Jan 2016.
  19. 19.
    Legris ME, Charbonneau-Séguin N, Desforges K, Sauvé P, Lord A, Bell R, et al. Quality of medication use in chronic kidney disease patients: Development and pilot testing of a web-based training program for community pharmacists. J Popl Ther Clin Pharmacol. 2011;18(2):e208.Google Scholar
  20. 20.
    Legris ME, Séguin NC, Desforges K, Sauvé P, Lord A, Bell R, et al. Pharmacist web-based training program on medication use in chronic kidney disease patients: Impact on knowledge, skills, and satisfaction. J Contin Educ Health Prof. 2011;31(3):140–50.CrossRefPubMedGoogle Scholar
  21. 21.
    Lalonde L, Normandeau M, Lamarre D, Lord A, Berbiche D, Corneille L, et al. Evaluation of a training and communication-network nephrology program for community pharmacists. Pharm World Sci. 2008;30(6):924–33.CrossRefPubMedGoogle Scholar
  22. 22.
    Abdel Shaheed C, Maher CG, Mak W, Williams KA, McLachlan AJ. The effects of educational interventions on pharmacists’ knowledge, attitudes and beliefs towards low back pain. Int J Clin Pharm. 2015;37(4):616–25.CrossRefPubMedGoogle Scholar
  23. 23.
    Jose J, Jimmy B, Al-Ghailani ASH. Al Majali MA. A cross sectional pilot study on assessing the knowledge, attitude and behavior of community pharmacists to adverse drug reaction related aspects in the Sultanate of Oman. Saudi Pharm J. 2014;22(2):163–9.CrossRefPubMedGoogle Scholar
  24. 24.
    Smith SD, Lee A, Blaszczynski A, Fischer G. Pharmacists’ knowledge about use of topical corticosteroids in atopic dermatitis: pre and post continuing professional development education. Australas J Dermatol. 2015.Google Scholar
  25. 25.
    Sears KE, Cohen JE, Drope J. Comprehensive evaluation of an online tobacco control continuing education course in Canada. J Contin Educ Health Prof. 2008;28(4):235–40.CrossRefPubMedGoogle Scholar
  26. 26.
    Abdulghani HM, Shaik SA, Khamis N, Al-Drees AA, Irshad M, Khalil MS, et al. Research methodology workshops evaluation using the Kirkpatrick’s model: translating theory into practice. Med Teach. 2014;36:S24–9.CrossRefPubMedGoogle Scholar
  27. 27.
    Kirkpatrick DL, Kirkpatrick JD. Evaluating Training Programs: The Four Levels. 3rd ed. USA: Berrett-Koehler Publishers; 2009.Google Scholar
  28. 28.
    Jaar BG, Khatib R, Plantinga L, Boulware LE, Powe NR. Principles of screening for chronic kidney disease. Clin J Am Soc Nephrol. 2008;3(2):601–9.CrossRefPubMedGoogle Scholar
  29. 29.
    Pharmaceutical Society of Australia. Early Career Pharmacists. Early Career Pharmacists survey Appendix B-qualitative data. 2010. Accessed 2 Dec 2015.

Copyright information

© Springer International Publishing 2016

Authors and Affiliations

  • Pankti A. Gheewala
    • 1
    Email author
  • Gregory M. Peterson
    • 1
  • Syed Tabish R. Zaidi
    • 1
  • Luke Bereznicki
    • 1
  • Matthew D. Jose
    • 2
  • Ronald L. Castelino
    • 1
  1. 1.Division of Pharmacy, School of Medicine, Faculty of HealthUniversity of TasmaniaHobartAustralia
  2. 2.School of Medicine, Faculty of HealthUniversity of TasmaniaHobartAustralia

Personalised recommendations